Week in Review: Cross-Border Deals Dominate the Week's News

Sino Biopharma plans to invest up to $129 million in Karolinska Development, a Stockholm company that supports translational drug development in Scandinavia; BioNano Genomics of San Diego raised $53 million in a Series C funding that was led by Beijing's Legend Capital; Yabao Pharma in-licensed greater China rights to a Parkinson's disease kinase target from MRC Technology of the UK; 3SBio acquired rights to an anti-angiogenesis antibody developed by Korea's PharmAbcine for Greater China and three emerging countries; Lee's Pharm of Hong Kong partnered with Ikaria, a US company, to develop Ikaria's Inomax® in greater China; Amgen completed construction of its new $200 million next-generation biomanufacturing facility in Singapore, which will cut costs by 60%; the leaders of the world's largest economies signed a trade agreement in Beijing to reduce tariffs and duties on medical devices, a pact that would eliminate import taxes of as much as 8% in China; and Suzhou Connect Biopharma began a Phase I clinical trial in Australia of CBP-307, an orally active molecule aimed at autoimmune diseases. More details.... Stock Symbols: (HK: 1177) (SS: KDEV) (SHA: 600351) (HK; 0950) (NSDQ: AMGN) Share this with colleagues: // //